美罗培南与亚胺培南治疗老年重度医院内肺炎临床评价

目的评价美罗培南和亚胺培南治疗老年重度医院内肺炎的有效性和安全性。方法共分析132例（53例美罗培南，79例亚胺培南；两药均为500mg，bid，ivgtt，疗程5～16d）老年重度医院内肺炎的临床疗效、细菌清除率、安全性和临床分离菌体外药敏试验。结果美罗培南和亚胺培南治疗老年重度医院内肺炎的总有效率分别为94．3％（50153）和88．6％（70／79），痊愈率为88．6％（47/53）和75．9％（60/79）。治疗前共分离细菌123株，美罗培南和亚胺培南对细菌的体外总敏感率为95．9％（118/123）和93．5％（87／93），细菌清除率为92．3％（48／52）和90．1％（64/71），不良反应发生率为9．4％（5/53）和12．6％（10／79），反应轻微（P〉0．05）。结论美罗培南和亚胺培南治疗老年重度医院内肺炎疗效确切且安全。

Clinical efficacy of meropenem and imipenem in the treatment of elderly patients with nosocomial pneumonia

Objective To evaluate the efficacy and safety of meropenem and imipenem in the treatment of elderly patients with nosocomial pneumonia. Methods A total of 132 elderly patients with nosocomial pneumonia were enrolled in this study, 53 cases were in meropenem group, and 79 cases were in imipenem group, meropenem and imipenem were administered, 500mg, bid, ivgtt, for 5-16 day, respectively. Results The effective rates of meropenem and imipenem were 94.3%and 88.6%; the bacterial eradication rates in the two groups were 92.3% and 90.1%; the clinical adverse effect rates were 9.4% and 12.6% in the two groups respectively. There was no statistical significance between the two groups. Conclusion Meropenem and imipenem are effective and well-tolerated in treatment of elderly nosocomial pneumonia.